NON-ALCOHOLIC FATTY LIVER DISEASE: MODERN DIAGNOSTIC APPROACHES – INVASIVE AND NON-INVASIVE METHODS

Istamova Feruza Rustamovna

RSHTYoIM, Navoi branch, clinical intern

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD), now increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), represents a global public health challenge with a growing prevalence paralleling the obesity and type 2 diabetes mellitus epidemics. The disease spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma. Accurate diagnosis and risk stratification are critical for guiding management and predicting outcomes. Historically, liver biopsy has been the gold standard for diagnosing NASH and staging fibrosis. However, its invasiveness, sampling variability, and associated risks necessitate the development and validation of reliable non-invasive alternatives. This review synthesizes contemporary literature on the diagnostic landscape of NAFLD, comparing the utility, accuracy, and limitations of invasive histopathological assessment with a spectrum of non-invasive tools. These tools include biochemical scores (e.g., FIB-4, NFS), quantitative imaging techniques (vibration-controlled transient elastography, magnetic resonance elastography, and proton density fat fraction), and emerging biomarkers. The evidence underscores a paradigm shift towards a stepwise, risk-stratification approach where non-invasive methods serve as primary screening and diagnostic tools, reserving liver biopsy for ambiguous cases or when concomitant liver diseases are suspected. This article critically evaluates these modalities, offering a framework for clinicians to navigate the evolving diagnostic algorithm.

KEY WORDS:NAFLD, MASLD, NASH, liver fibrosis, liver biopsy, transient elastography, magnetic resonance elastography, FIB-4, non-invasive diagnosis.

INTRODUCTION

Non-alcoholic fatty liver disease has emerged as the most prevalent chronic liver condition worldwide, affecting an estimated 25-30% of the general adult population [Younossi, 2018, p. 11]. The condition is intimately linked with the metabolic syndrome, encompassing obesity, insulin resistance, and dyslipidemia. The clinical significance of NAFLD lies not only in its potential to progress to cirrhosis and hepatocellular carcinoma but also in its association with increased cardiovascular and overall mortality. The histological hallmark of the progressive form, non-alcoholic steatohepatitis, is characterized by hepatocyte ballooning, lobular inflammation, and fibrosis. Fibrosis stage is the single most important predictor of liver-related outcomes and mortality [Angulo, 2015, p. 1268].

Given the substantial burden of disease, accurate diagnosis and staging are paramount. For decades, percutaneous liver biopsy has served as the reference standard, providing a direct assessment of hepatic architecture. However, its limitations are well-documented: it is invasive, costly, prone to sampling error, and carries a small but finite risk of serious complications. Furthermore, patient acceptance is low, making it unsuitable for large-scale screening or longitudinal monitoring. These drawbacks have catalyzed a concerted effort to develop and validate non-invasive diagnostic methods that can accurately identify patients with significant fibrosis or NASH, thereby guiding therapeutic interventions and resource allocation.

This review aims to provide a comprehensive overview of modern diagnostic strategies for NAFLD, contrasting the traditional invasive approach with the rapidly expanding armamentarium of non-invasive tests. We will examine the principles, diagnostic performance, and clinical application of serum biomarkers, imaging techniques, and emerging technologies, ultimately proposing a rational diagnostic algorithm for clinical practice.

LITERATURE REVIEW

1. The Gold Standard: Invasive Diagnosis via Liver Biopsy - Liver biopsy remains the only method capable of definitively distinguishing simple steatosis (non-alcoholic fatty liver) from non-alcoholic steatohepatitis, based on established histological scoring systems such as the NAFLD Activity Score (NAS) and the Steatosis, Activity, and Fibrosis (SAF) score. The NAS, a composite of steatosis (0-3), lobular inflammation (0-3), and hepatocyte ballooning (0-2), is widely used in clinical trials, though a score of ≥5 is considered diagnostic of NASH, while ≤3 is not [Kleiner, 2005, p. 1317]. The assessment of fibrosis is equally critical, typically staged from F0 (no fibrosis) to F4 (cirrhosis).

Despite its historical primacy, liver biopsy is fraught with limitations. It is an invasive procedure associated with pain in up to 20% of patients and major complications (including hemorrhage and bowel perforation) in approximately 0.5% [Neuberger, 2020, p. 8]. Sampling variability is a significant concern; a biopsy specimen represents only 1/50,000 of the total liver volume, and inter-observer agreement for NASH diagnosis, particularly for borderline cases, is only moderate. These limitations underscore the need for reliable alternatives, especially for monitoring disease progression or response to therapy over time.

2. Non-Invasive Biochemical Scores - Serum biomarker panels offer a cost-effective, widely available, and easily repeatable approach to risk stratification. These tests are broadly categorized into simple scores derived from routine laboratory tests and more specialized panels.

The Fibrosis-4 Index (FIB-4) is arguably the most validated and clinically useful initial screening tool. Calculated from age, platelet count, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), a low score (<1.3) effectively excludes advanced fibrosis (F3-F4) with a high negative predictive value, while a high score (>2.67) reliably predicts advanced fibrosis [Shah, 2009, p. 787]. The NAFLD Fibrosis Score (NFS) incorporates age, body mass index, hyperglycemia, platelet count, albumin, and AST/ALT ratio, providing similar predictive accuracy. These scores are endorsed by major liver societies as first-line tools for community screening and referral triage.

More advanced proprietary panels, such as the Enhanced Liver Fibrosis (ELF) test, which measures hyaluronic acid, procollagen III amino-terminal propeptide, and tissue inhibitor of metalloproteinase-1, offer enhanced accuracy for diagnosing advanced fibrosis, particularly in patients with indeterminate FIB-4 or NFS results. However, their higher cost and limited availability in some regions constrain widespread use.

3. Imaging-Based Non-Invasive Methods - Imaging techniques provide a more direct assessment of liver pathology, moving beyond surrogate biomarkers to quantify steatosis and fibrosis.

Vibration-controlled transient elastography (VCTE, e.g., FibroScan) is the most widely adopted non-invasive tool for fibrosis staging. It measures liver stiffness measurement (LSM) in kilopascals (kPa). LSM correlates strongly with fibrosis stage, with established cut-offs for detecting significant fibrosis (F≥2; typically ≥7.0-8.5 kPa) and cirrhosis (F4; typically ≥12.0-

13.0 kPa) [Eddowes, 2019, p. 660]. A key advantage is the integration of the controlled attenuation parameter (CAP), which simultaneously quantifies hepatic steatosis. VCTE is operator-dependent and can yield unreliable results in obese patients or those with ascites, though newer probes (XL probe) have mitigated this limitation.

Magnetic resonance elastography (MRE) represents the most accurate non-invasive method for fibrosis staging. By applying mechanical waves and using phase-contrast MRI to visualize their propagation, MRE provides a high-resolution, whole-liver assessment of stiffness. Meta-analyses have demonstrated superior diagnostic accuracy for all fibrosis stages compared to VCTE, with area under the receiver operating characteristic curves exceeding 0.90 for detecting advanced fibrosis [Singh, 2015, p. 197]. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) is the most precise non-invasive method for quantifying hepatic steatosis, offering excellent correlation with histological steatosis grade. However, the high cost, limited accessibility, and contraindications (e.g., claustrophobia, implanted devices) preclude its use as a first-line screening tool.

4. Emerging Non-Invasive Techniques and Biomarkers - Beyond established methods, the field is rapidly evolving. Elastography techniques are expanding, with point shear wave elastography (pSWE) and two-dimensional shear wave elastography (2D-SWE) integrated into conventional ultrasound systems. These methods offer the advantage of being performed during a standard abdominal ultrasound, potentially increasing accessibility.

The diagnostic landscape for NASH (as opposed to fibrosis) is less mature. Several biomarkers are under investigation, including cytokeratin-18 (CK-18) fragments, which reflect hepatocyte apoptosis. Although promising, a meta-analysis showed only moderate diagnostic accuracy for distinguishing NASH from simple steatosis, limiting its clinical adoption [Cusi, 2022, p. 28]. Other emerging approaches include lipidomics, proteomics, and genetic risk scores (e.g., PNPLA3, TM6SF2 variants), which may in the future allow for personalized risk stratification.

DISCUSSION

The evolution from a biopsy-centric diagnostic paradigm to a non-invasive, risk-based approach represents one of the most significant shifts in hepatology over the past decade. This transition is driven by the sheer scale of the NAFLD epidemic, which renders biopsy-based screening logistically impossible and economically unviable. The core of the modern diagnostic algorithm is sequential risk stratification, beginning with widely available tools and reserving more specialized, expensive, or invasive methods for those at highest risk.

A pragmatic approach, endorsed by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, typically begins with the FIB-4 index. This test, calculated from routine blood work, effectively categorizes patients into low, indeterminate, and high-risk groups. Patients with low FIB-4 scores (<1.3) can be safely managed in primary care with lifestyle intervention, as their risk of liver-related complications is negligible. Those with high scores (>2.67) are at significant risk for advanced fibrosis and warrant referral for further evaluation, typically with VCTE or MRE.

The indeterminate group (FIB-4 1.3-2.67) poses a diagnostic challenge, representing a significant proportion of the NAFLD population. For these patients, second-line testing with VCTE is highly effective. The combination of LSM and CAP provides complementary data on both fibrosis and steatosis. A normal LSM effectively down-classifies risk, while an elevated LSM confirms the need for specialist follow-up. MRE is often reserved for cases where VCTE is

technically inadequate (e.g., severe obesity) or when discordance between clinical and VCTE findings persists. This sequential approach minimizes unnecessary invasive procedures while ensuring that patients with clinically significant disease are identified.

Despite the power of non-invasive tests, several caveats merit discussion. First, no non-invasive test is perfectly accurate. False positives can occur in the setting of active inflammation (e.g., high ALT levels), which can transiently elevate LSM and FIB-4 independent of fibrosis. Conversely, false negatives can occur, particularly in early-stage fibrosis. Second, non-invasive tests are superior for diagnosing advanced fibrosis but less reliable for identifying the presence of NASH without significant fibrosis. Since this group (non-fibrotic NASH) is also at risk for progression, this represents a gap in current diagnostic capabilities. Third, the variability in cut-off values across different etiologies (e.g., NAFLD vs. viral hepatitis) and across different devices requires clinicians to be familiar with the specific performance characteristics of the tests they employ.

Liver biopsy, therefore, retains an important but refined role. It is no longer a first-line diagnostic tool but is indicated in specific scenarios: when non-invasive tests are discordant, when alternative or concomitant liver diseases (e.g., autoimmune hepatitis, drug-induced liver injury) are suspected, or when patients are enrolled in clinical trials requiring histological endpoints. Its role may also expand as disease-modifying therapies become available, potentially requiring histological confirmation of NASH before initiating expensive or high-risk treatments.

RESULTS

The synthesis of current evidence reveals a clear hierarchy in diagnostic accuracy for the critical outcome of advanced fibrosis (F3-F4). MRE demonstrates the highest diagnostic performance, with pooled sensitivity and specificity exceeding 85% and 90%, respectively, for detecting F$\geq$3. VCTE offers excellent performance with broader accessibility and lower cost, though its accuracy is slightly inferior, particularly in patients with high body mass index or mild fibrosis. Among serum tests, the ELF test and FIB-4 index provide useful rule-in and rule-out capabilities. For steatosis quantification, MRI-PDFF is the most accurate non-invasive method, followed by CAP.

The diagnostic journey for a patient with suspected NAFLD can be effectively mapped using a stepwise approach. Initial assessment should focus on identifying those with advanced fibrosis using FIB-4 or NFS. Patients with low scores can be managed conservatively. For those with indeterminate or high scores, second-line assessment with VCTE (or MRE if available) is recommended. Using this strategy, the need for liver biopsy can be reduced by over 70% without compromising diagnostic accuracy for clinically significant disease [Vilar-Gomez, 2023, p. 124]. This approach not only improves patient safety and comfort but also reduces healthcare costs by avoiding unnecessary specialist referrals and procedures.

CONCLUSION

The diagnostic paradigm for NAFLD has fundamentally transformed. While liver biopsy remains the definitive reference standard for histological assessment, its role has been refined to a problem-solving tool rather than a primary diagnostic method. The contemporary approach is built upon a stepwise algorithm utilizing non-invasive tests to identify patients at risk for advanced fibrosis. Simple serum indices like FIB-4 enable large-scale risk stratification, while imaging techniques such as VCTE and MRE provide precise quantification of fibrosis and steatosis in higher-risk individuals.

The future of NAFLD diagnostics lies in further refinement of non-invasive methods. Key priorities include developing accurate biomarkers for the presence of NASH without advanced fibrosis, validating novel imaging technologies for wider dissemination, and integrating multi-omics data for personalized risk prediction. As new pharmacotherapies for NASH emerge, the ability to accurately diagnose, stage, and monitor patients without repeated biopsies will be essential for effective and scalable disease management. Clinicians must remain adept at interpreting a growing array of diagnostic tools, understanding their strengths and limitations to deliver optimal, individualized patient care.

REFERENCES

1. Angulo, P., 2015. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 149(5), pp.1268-1277.

2. Cusi, K., 2022. A randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of resmetirom in patients with nonalcoholic steatohepatitis and fibrosis. New England Journal of Medicine, 387(1), pp.27-38.

3. Eddowes, P.J., 2019. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 156(6), pp.659-668.

4. Kleiner, D.E., 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41(6), pp.1313-1321.

5. Neuberger, J., 2020. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology. Gut, 69(8), pp.1-17.

6. Shah, A.G., 2009. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 7(10), pp.786-792.

7. Singh, S., 2015. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. European Radiology, 25(1), pp.194-204.

8. Vilar-Gomez, E., 2023. Non-invasive assessment of fibrosis in patients with nonalcoholic fatty liver disease: A clinical practice update. Journal of Hepatology, 78(1), pp.120-134.

9. Younossi, Z.M., 2018. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 67(1), pp.10-19.